Traphagen Investment Advisors LLC Cuts Stake in Pfizer Inc. $PFE

Traphagen Investment Advisors LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 4.7% during the second quarter, Holdings Channel.com reports. The institutional investor owned 26,303 shares of the biopharmaceutical company’s stock after selling 1,284 shares during the period. Traphagen Investment Advisors LLC’s holdings in Pfizer were worth $638,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new position in shares of Pfizer in the 1st quarter worth about $27,000. Bayforest Capital Ltd purchased a new stake in Pfizer during the first quarter valued at about $28,000. North Capital Inc. purchased a new stake in Pfizer during the first quarter valued at about $28,000. WPG Advisers LLC purchased a new stake in Pfizer during the first quarter valued at about $35,000. Finally, Horizon Financial Services LLC purchased a new stake in Pfizer during the first quarter valued at about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.6%

Shares of Pfizer stock opened at $26.27 on Wednesday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a market cap of $149.36 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 0.86 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company’s 50-day moving average price is $24.76 and its 200-day moving average price is $24.14.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. Bank of America upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Morgan Stanley increased their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.